Pediatric Drugs

, Volume 20, Issue 2, pp 111–120 | Cite as

Agents in Development for Childhood Acute Lymphoblastic Leukemia

Review Article
First Online:
  • 281 Downloads

Abstract

Acute lymphoblastic leukemia (ALL) is the most common cancer in childhood. Standard chemotherapy has afforded outstanding outcomes for many patients; however, there remain some sub-groups with high-risk features, refractory disease, and patients that  relapse who have a poor prognosis with conventional treatments. Over the past decade, there have been significant advances in newer treatment options, including improved monoclonal antibody therapies, T cell engagers, and chimeric antigen T-cell receptor products, all of which have changed the landscape for patients who relapse. These are now being introduced more frequently and at earlier stages of therapy. We present a brief overview of the biology and etiology of childhood ALL, treatment strategies currently in use, and discuss some newer strategies and their possible role in the future of ALL therapy for children.

This is a preview of subscription content, log in to check access.

Notes

Compliance with Ethical Standards

Funding

No funding and no editorial services were paid for or received for the preparation of this manuscript. LG is the recipient of the Clark and Ergen Family Endowed Chairs from the Children’s Hospital Colorado Foundation.

Conflict of interest

Dr Maloney has no relevant conflicts of interest to declare. Dr Gore has the following conflicts of interest to declare: service on Data Safety Monitoring Boards for Novartis for tisagenlecleucel and for Celgene for an oncology product unrelated to the topic of this manuscript; Advisory Board service for Amgen, Celgene, Novartis for possible development of various oncology products for treatment of childhood leukemia; stock in Amgen, Inc. purchased in 1996 without further trade or sale since that time.

References

  1. 1.
    Hunger SP, Lu X, Devidas M, Camitta BN, Gaynon PS, Winick NJ, Reaman GH, Carroll WL. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the Children’s Oncology Group. J Clin Oncol. 2012;30(14):1663–9.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Smith M, Arthur D, Camitta B. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol. 1996;14:18–24.CrossRefPubMedGoogle Scholar
  3. 3.
    Borowitz MJ, Wood BL, Devidas M, Loh ML, Raetz EA, Salzer WL, Nachman JB, Carroll AJ, Heerema NA, Gastier-Foster JM, Willman CL, Dai Y, Winick NJ, Hunger SP, Carroll WL, Larsen E. Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children’s Oncology Group study AALL0232. Blood. 2017;126:964–71.CrossRefGoogle Scholar
  4. 4.
    Pui CH, Yang JJ, Hunger SP, Pieters R, Schrappe M, Biondi A, Vora A, Baruchel A, Silverman LB, Schmiegelow K, Escherich G, Horibe K, Benoit YC, Izraeli S, Yeoh AE, Liang DC, Downing JR, Evans WE, Relling MV, Mullighan CG. Childhood acute lymphoblastic leukemia: progress through collaboration. J Clin Oncol. 2015;33:2938–48.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Vora A, Goulden N, Mitchell C, Hancock J, Hough R, Rowntree C, Moorman AV, Wade R. Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomized controlled trial. Lancet Oncol. 2014;15(8):809–18. doi: 10.1016/S1470-2045(14)70243-8 Epub 2014 Jun 9.CrossRefPubMedGoogle Scholar
  6. 6.
    Pui CH, Pei D, Coustan-Smith E, Jeha S, Cheng C, Bowman WP, Sandlund JT, Ribeiro RC, Rubnitz JE, Inaba H, Bhojwani D, Gruber TA, Leung WH, Downing JR, Evans WE, Relling MV, Campana D. Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study. Lancet Oncol. 2015;16(4):465–74. doi: 10.1016/S1470-2045(15)70082-3 Epub 2015 Mar 20.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Schrappe M. Detection and management of minimal residual disease in acute lymphoblastic leukemia. Hematol Am Soc Hematol Educ Progr. 2014;2014(1):244–9. doi: 10.1182/asheducation-2014.1.244 Epub 2014 Nov.Google Scholar
  8. 8.
    Tasian S, Hunger SP. Genomic characterization of paediatric acute lymphoblastic leukaemia: an opportunity for precision medicine therapeutics. Br J Haematol. 2017;176(6):867–882. doi: 10.1111/bjh.14474 (Epub 2016 Dec 16. Review).
  9. 9.
    Golub TR, Barker GF, Bohlander SK, Hiebert SW, Ward DC, Bray-Ward P, Morgan E, Raimondi SC, Rowley JD, Gilliland DG. Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia. Proc Natl Acad Sci. 1995;92(11):4917–21.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Loh ML, Rubnitz JE. TEL/AML1-positive pediatric leukemia: prognostic significance and therapeutic approaches. Curr Opin Hematol. 2002;9(4):345–52.CrossRefPubMedGoogle Scholar
  11. 11.
    Hunger SP, Mullighan CG. Acute lymphoblastic leukemia in children. N Engl J Med. 2015;373:1541–52. doi: 10.1056/NEJMra1400972.CrossRefPubMedGoogle Scholar
  12. 12.
    Guest EM, Stam RW. Updates in the biology and therapy for infant acute lymphoblastic leukemia. Curr Opin Pediatr. 2017;29(1):20–6. doi: 10.1097/MOP.0000000000000437.CrossRefPubMedGoogle Scholar
  13. 13.
    Winters AC, Bernt KM. MLL-rearranged leukemias—an update on science and clinical approaches. Front Pediatr. 2017;5:4. doi: 10.3389/fped.2017.00004 (eCollection 2017).
  14. 14.
    Mullighan CG, Jeha S, Pei D, Payne-Turner D, Coustan-Smith E, Roberts KG, Waanders E, Choi JK, Ma X, Raimond SC, Fan Y, Yang W, Song G, Yang JJ, Inaba H, Downing JR, Leung WH, Bowman WP, Relling MV, Evans WE, Zhang J, Campana D, Pui CH. Outcome of children with hypodiploid ALL treated with risk-directed therapy based on MRD levels. Blood. 2015;126(26):2896–9. doi: 10.1182/blood-2015-09-671131.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Schultz KR, Carroll A, Heerema NA, Bowman WP, Aledo A, Slayton WB, Sather H, Devidas M, Zheng HW, Davies SM, Gaynon PS, Trigg M, Rutledge R, Jorstad D, Winick N, Borowitz MJ, Hunger SP, Carroll WL, Camitta B. Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children’s Oncology Group study AALL0031. Leukemia. 2014;28(7):1467–71. doi: 10.1038/leu.2014.30 Epub 2014 Jan 20.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Mullighan CG, Collins-Underwood JR, Phillips LA, Loudin MG, Liu W, Zhang J, Ma J, Coustan-Smith E, Harvey RC, Willman CL, Mikhail FM, Meyer J, Carroll AJ, Williams RT, Cheng J, Heerema NA, Basso G, Pession A, Pui CH, Raimondi SC, Hunger SP, Downing JR, Carroll WL, Rabin KR. Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia. Nat Genet. 2009;41(11):1243–6. doi: 10.1038/ng.469 Epub 2009 Oct 18 PMID:19838194.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Roberts KG, Li Y, Payne-Turner D, Harvey RC, Yang YL, Pei D, McCastlain K, Ding L, Lu C, Song G, Ma J, Becksfort J, Rusch M, Chen SC, Easton J, Cheng J, Boggs K, Santiago-Morales N, Iacobucci I, Fulton RS, Wen J, Valentine M, Cheng C, Paugh SW, Devidas M, Chen IM, Reshmi S, Smith A, Hedlund E, Gupta P, Nagahawatte P, Wu G, Chen X, Yergeau D, Vadodaria B, Mulder H, Winick NJ, Larsen EC, Carroll WL, Heerema NA, Carroll AJ, Grayson G, Tasian SK, Moore AS, Keller F, Frei-Jones M, Whitlock JA, Raetz EA, White DL, Hughes TP, Guidry Auvil JM, Smith MA, Marcucci G, Bloomfield CD, Mrózek K, Kohlschmidt J, Stock W, Kornblau SM, Konopleva M, Paietta E, Pui CH, Jeha S, Relling MV, Evans WE, Gerhard DS, Gastier-Foster JM, Mardis E, Wilson RK, Loh ML, Downing JR, Hunger SP, Willman CL, Zhang J, Mullighan CG. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med. 2014;371(11):1005–15. doi: 10.1056/NEJMoa1403088 PMID:25207766.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Chang JS, Tsai YW, Tsai CR, Wiemels JL. Allergy and risk of childhood acute lymphoblastic leukemia: a population-based and record-based study. Am J Epidemiol. 2012;176(11):970–8. doi: 10.1093/aje/kws263 Epub 2012 Nov 20.CrossRefPubMedGoogle Scholar
  19. 19.
    Schüz J, Erdmann F. Environmental exposure and risk of childhood leukemia: an overview. Arch Med Res. 2016;47(8):607–14. doi: 10.1016/j.arcmed.2016.11.017.CrossRefPubMedGoogle Scholar
  20. 20.
    Porter CC, Druley TE, Erez A, Kuiper RP, Onel K, Schiffman JD, Wolfe-Schneider K, Scollon SR, Scott HS, Strong LC, Walsh MF, Nichols KE. Recommendations for surveillance for children with leukemia-predisposing conditions. Clin Cancer Res. 2017;23(11):e14–22. doi: 10.1158/1078-0432.CCR-17-0428.CrossRefPubMedGoogle Scholar
  21. 21.
    Maloney KW. Acute lymphoblastic leukaemia in children with Down syndrome: an updated review. Br J Haematol. 2011;155(4):420–5.CrossRefPubMedGoogle Scholar
  22. 22.
    Pui C, Pei D, Sandlund JT, Ribeiro RC, Rubnitz JE, Raimondi SC, Onciu M, Campana D, Kun LE, Jeha S, Cheng C, Howard SC, Metzger ML, Bhojwani D, Downing JR, Evans WE, Relling MV. Long-term results of St Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia. Leukemia. 2010;24(2):371–82. doi: 10.1038/leu.2009.252 Epub 2009 Dec 10.CrossRefPubMedGoogle Scholar
  23. 23.
    Möricke A, Zimmermann M, Reiter A, Henze G, Schrauder A, Gadner H, Ludwig WD, Ritter J, Harbott J, Mann G, Klingebiel T, Zintl F, Niemeyer C, Kremens B, Niggli F, Niethammer D, Welte K, Stanulla M, Odenwald E, Riehm H, Schrappe M. Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia. 2010;24(2):265–84. doi: 10.1038/leu.2009.257 Epub 2009 Dec 10.CrossRefPubMedGoogle Scholar
  24. 24.
    Larsen EC, Devidas M, Chen S, Salzer WL, Raetz EA, Loh ML, Mattano LA, Cole C, Eicher A, Haugan M, Sorenson M, Heerema NA, Carroll AA, Gastier-Foster JM, Borowitz MJ, Wood BL, Willman CL, Winick NJ, Hunger SP, Carroll WL. Dexamethasone and high-dose methotrexate improve outcome for children and young adults with high-risk b-acute lymphoblastic leukemia: a report from Children’s Oncology Group Study AALL0232. J Clin Oncol. 2016;34(20):2380–8. doi: 10.1200/JCO.2015.62.4544 Epub 2016 Apr 25.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Vrooman LM, Stevenson KE, Supko JG, O’Brien J, Dahlberg SE, Asselin BL, Athale UH, Clavell LA, Kelly KM, Kutok JL, Laverdière C, Lipshultz SE, Michon B, Schorin M, Relling MV, Cohen HJ, Neuberg DS, Sallan SE, Silverman L. Postinduction dexamethasone and individualized dosing of Escherichia Coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study–Dana-Farber Cancer Institute ALL Consortium Protocol 00-01. J Clin Oncol. 2013;31(9):1202–10. doi: 10.1200/JCO.2012.43.2070 Epub 2013 Jan 28.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Pieters R, de Groot-Kruseman H, Van der Velden V, Fiocco M, van den Berg H, de Bont E, Egeler RM, Hooerbrugge P, Kaspers G, Van der Schoot E, De Haas V, Van Dongen J. Successful therapy reduction and intensification for childhood acute lymphoblastic leukemia based on minimal residual disease monitoring: study ALL10 from the Dutch Childhood Oncology Group. J Clin Oncol. 2015;34(22):2591–601. doi: 10.1200/JCO.2015.64.6364 PMID: 27269950.CrossRefGoogle Scholar
  27. 27.
    Schrappe M, Zimmermann M, Möricke A, Mann G, Valsecchi MG, Bartram CR, Biondi A, Panzer-Grümayer R, Beier R, Cario G, Locatelli F, Basso G, Niggli F, Aricò M, Conter V. Reduced intensity delayed intensification in standard-risk patients defined by minimal residual disease in childhood acute lymphoblastic leukemia: results of an International randomized trial in 1164 patients (Trial AIEOP-BFM ALL 2000). Hematology Am Soc Hematol Educ Program. 2016. doi:asheducation-2016 (Epub 2016 Nov).Google Scholar
  28. 28.
    Chessells JM. Relapsed lymphoblastic leukaemia in children: a continuing challenge. Br J Haematol. 1998;102(2):423–38.CrossRefPubMedGoogle Scholar
  29. 29.
    Kersey JH, LeBien TW, Abramson CS, Newman R, Sutherland R, Greaves M. p24: a human leukemia-associated and lymphohemopoietic progenitor cell surface structure identified with monoclonal antibody. J Exp Med. 1981;153:726–31.CrossRefPubMedGoogle Scholar
  30. 30.
    Richter-Pechańska P, Kunz JB, Hof J, Zimmermann M, Rausch T, Bandapalli OR, Orlova E, Scapinello G, Sagi JC, Stanulla M, Schrappe M, Cario G, Kirschner-Schwabe R, Eckert C, Benes V, Korbel JO, Muckenthaler MU, Kulozik AE. Identification of a genetically defined ultra-high-risk group in relapsed pediatric T-lymphoblastic leukemia. Blood Cancer J. 2017;7(2):e523. doi: 10.1038/bcj.2017.3.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    LeBien TW, Boue DR, Bradley JG, Kersey JH. Antibody affinity may influence antigenic modulation of the common acute lymphoblastic leukemia antigen in vitro. J Immunol. 1982;129(5):2287–92.PubMedGoogle Scholar
  32. 32.
    Uckun FM, Manivel C, Arthur D, Chelstrom LM, Finnegan D, Tuel-Ahlgren L, Irvin JD, Myers DE, Gunther R. In vivo efficacy of B43 (anti-CD19)-pokeweed antiviral protein immunotoxin against human pre-B cell acute lymphoblastic leukemia in mice with severe combined immunodeficiency. Blood. 1992;79(9):2201–14.Google Scholar
  33. 33.
    Mackall CL, Merchant M, Fry TJ. Immune-based therapies for childhood cancer. Nat Rev Clin Oncol. 2014;11(12):693–703. doi: 10.1038/nrclinonc.2014.177 (Epub 2014 Oct 28).
  34. 34.
    Qin H, Cho M, Haso W, Zhang L, Tasian SK, Oo HZ, Negri GL, Lin Y, Zou J, Mallon BS, Maude S, Teachey DT, Barrett DM, Orentas RJ, Daugaard M, Sorensen PH, Grupp SA, Fry TJ. Eradication of B-ALL using chimeric antigen receptor-expressing T cells targeting the TSLPR oncoprotein. Blood. 2015;126(5):629–39. doi: 10.1182/blood-2014-11-612903 Epub 2015 Jun 3.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Dworzak MN, Schumich A, Printz D, Poschger U, Husak Z, Attarbaschi A, Basso G, Gaipa G, Ratei R, Mann G, Gadner H. CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti-CD20 directed immunotherapy. Blood. 2008;112:3982–3988.Google Scholar
  36. 36.
    Carnahan J, Wang P, Kendall R, Chen C, Hu S, Boone T, Juan T, Talvenheimo J, Montestruque S, Sun J, Elliott G, Thomas J, Ferbas J, Kern B, Briddell R, Leonard JP, Cesano A. Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties. Clin Cancer Res. 2003;9:3982S–90S.PubMedGoogle Scholar
  37. 37.
    Raetz EA, Cairo MS, Borowitz MJ, Blaney SM, Krailo MD, Leil TA, Reid JM, Goldenberg DM, Wegener WA, Carroll WL. Chemoimmunotherapy reinduction with Epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children’s Oncology Group pilot study. J Clin Oncol. 2008;26(22):3756–62. doi: 10.1200/JCO.2007.15.3528.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Raetz EA, Cairo MS, Borowitz MJ, Lu X, Devidas M, Reid JM, Goldenberg DM, Wegener WA, Zeng H, Whitlock JA, Adamson PC, Hunger SP, Carroll WL. Re-induction chemoimmunotherapy with epratuzumab in relapsed acute lymphoblastic leukemia (ALL): phase II results from Children’s Oncology Group (COG) study ADVL04P2. Pediatr Blood Cancer. 2015;62:1171–5. doi: 10.1002/pbc.25454.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Kantarjian HM, DeAngelo DJ, Stelljes M, Martinelli G, Liedtke M, Stock W, Gökbuget N, O’Brien S, Wang K, Wang T, Paccagnella ML, Sleight B, Vandendries E, Advani AS. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med. 2016;375:740–53. doi: 10.1056/NEJMoa1509277.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Maury S, Chevret S, Thomas X, Heim D, Leguay T, Huguet F, Chevallier P, Hunault M, Boissel N, Escoffre-Barbe M, Hess U, Vey N, Pignon J-M, Braun T, Marolleau J-P, Cahn J-Y, Chalandon Y, Lhéritier V, Beldjord K, Béné MC, Ifrah N, Dombret H, for GRAALL. Rituximab in B-lineage adult acute lymphoblastic leukemia. N Engl J Med. 2016;375:1044–53. doi: 10.1056/NEJMoa1605085.CrossRefPubMedGoogle Scholar
  41. 41.
    Maude SL, Barrett D, David T, Teachey DT, Grupp SA. Managing cytokine release syndrome associated with novel T cell-engaging therapies. Cancer J. 2014;20(2):119–22. doi: 10.1097/PPO.0000000000000035.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Maude SL, Teachey DT, Porter DL, Grupp SA. CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Blood. 2015;125(26):4017–23. doi: 10.1182/blood-2014-12-580068 Epub 2015 May 21 PMID:25999455.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Topp MS, Gökbuget N, Zugmaier G, Klappers P, Stelljes M, Neumann S, Viardot A, Marks R, Diedrich H, Faul C, Reichle A, Horst HA, Brüggemann M, Wessiepe D, Holland C, Alekar S, Mergen N, Einsele H, Hoelzer D, Bargou RC. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J Clin Oncol. 2014;32(36):4134–40. doi: 10.1200/JCO.2014.56.3247 Epub 2014 Nov 10 PMID:25385737.CrossRefPubMedGoogle Scholar
  44. 44.
    Topp MS, Gökbuget N, Stein AS, Zugmaier G, O’Brien S, Bargou RC, Dombret H, Fielding AK, Heffner L, Larson RA, Neumann S, Foà R, Litzow M, Ribera JM, Rambaldi A, Schiller G, Brüggemann M, Horst HA, Holland C, Jia C, Maniar T, Huber B, Nagorsen D, Forman SJ, Kantarjian HM. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. 2015;16(1):57–66. doi: 10.1016/S1470-2045(14)71170-2. (Epub 2014 Dec 16. Erratum in: Lancet Oncol. 2015 Apr;16(4): e158. PMID:25524800).
  45. 45.
    von Stackelberg A, Locatelli F, Zugmaier G, Handgretinger R, Trippett TM, Rizzari C, P Bader, O’Brien M, Brethon B, Bhojwani D, Schlegel PG, Borkhardt A, Rheingold SR, Cooper TM, Zwaan CM, Barnette P, Messina C, Michel G, DuBois SG, Kuolung Hu K, Zhu M, Whitlock JA, Gore L. 2016. A phase 1/phase 2 study of blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia. J Clin Oncol 34(36):4381–4389. doi: 10.1200/JCO.2016.67.3301.
  46. 46.
    Teachey D, Rheingold SR, Maude SL, Barrett DM, Seif AE, Nichols KE, Suppa EK, Kalos M, Aplenc R, Gore L, Grupp SA. Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine directed therapy. Blood. 2013;121(26):5154–7. doi: 10.1182/blood-2013-02-485623 (Epub 2013 May 15).
  47. 47.
    Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K, Chung SS, Stefanski J, Borquez-Ojeda O, Olszewska M, Qu J, Wasielewska T, He Q, Fink M, Shinglot H, Youssif M, Satter M, Wang Y, Hosey J, Quintanilla H, Halton E, Bernal Y, Bouhassira DC, Arcila ME, Gonen M, Roboz GJ, Maslak P, Douer D, Frattini MG, Giralt S, Sadelain M, Brentjens R. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014;6(224):224ra25. doi: 10.1126/scitranslmed.3008226.
  48. 48.
    Przepiorka D, Ko CW, Deisseroth A, Yancey CL, Candau-Chacon R, Chiu HJ, Gehrke BJ, Gomez-Broughton C, Kane RC, Kirshner S, Mehrotra N, Ricks TK, Schmiel D, Song P, Zhao P, Zhou Q, Farrell AT, Pazdur R. FDA approval: blinatumomab. Clin Cancer Res. 2015;21(18):4035–9. doi: 10.1158/1078-0432.CCR-15-0612.CrossRefPubMedGoogle Scholar
  49. 49.
    Sanford M. Blinatumomab: first global approval. Drugs. 2015;75(3):321–7. doi: 10.1007/s40265-015-0356-3.CrossRefPubMedGoogle Scholar
  50. 50.
    Zugmaier G, Topp MS, Alekar S, Viardot A, Horst HA, Neumann S, Stelljes M, Bargou RC, Goebeler M, Wessiepe D, Degenhard E, Gökbuget N, Klinger M. Long-term follow-up of serum immunoglobulin levels in blinatumomab-treated patients with minimal residual disease-positive B-precursor acute lymphoblastic leukemia. Blood Cancer J. 2014;5(4):244. doi: 10.1038/bcj.2014.64.CrossRefGoogle Scholar
  51. 51.
    Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, Fry TJ, Orentas R, Sabatino M, Shah NN, Steinberg SM, Stroncek D, Tschernia N, Yuan C, Zhang H, Zhang L, Rosenberg SA, Wayne AS, Mackall CL. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2015;385(9967):517–28. doi: 10.1016/S0140-6736(14)61403-3 (Epub 2014 Oct 13).CrossRefPubMedGoogle Scholar
  52. 52.
    Paszkiewicz PJ, Fräßle SP, Srivastava S, Sommermeyer D, Hudecek M, Drexler I, Sadelain M, Liu L, Jensen MC, Riddell SR, Busch DH. Targeted antibody-mediated depletion of murine CD19 CAR T cells permanently reverses B cell aplasia. J Clin Invest. 2016;126(11):4262–72. doi: 10.1172/JCI84813 (Epub 2016 Oct 17).CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Tasian SK, Teachey DT, Li Y, Shen F, Harvey RC, Chen IM, Ryan T, Vincent TL, Willman CL, Perl AE, Hunger SP, Loh ML, Carroll M, Grupp SA. Potent efficacy of combined PI3 K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia. Blood. 2017;129(2):177–187. doi: 10.1182/blood-2016-05-707653 (Epub 2016 Oct 24).
  54. 54.
    Pui CH, Roberts KG, Yang JJ, Mullighan CG. Philadelphia chromosome-like acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk. 2017;17(8):464–70. doi: 10.1016/j.clml.2017.03.299.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  1. 1.Center for Cancer and Blood Disorders, Children’s Hospital Colorado, Pediatric Hematology/Oncology/Bone Marrow TransplantUniversity of Colorado School of MedicineAuroraUSA

Personalised recommendations